Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It is one of the four stereoisomers of EPI-001. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.
